ALT — Altimmune Income Statement
0.000.00%
Last trade - 00:00
- $489.89m
- $292.07m
- $0.43m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.8 | 8.19 | 4.41 | -0.068 | 0.426 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 27.3 | 63 | 101 | 87.7 | 96.4 |
Operating Profit | -21.5 | -54.8 | -96.9 | -87.7 | -95.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.6 | -54.5 | -97.1 | -84.9 | -88.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.5 | -49 | -97.1 | -84.7 | -88.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.5 | -49 | -97.1 | -84.7 | -88.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -21 | -49 | -97.1 | -84.7 | -88.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.55 | -1.91 | -2.08 | -1.81 | -1.43 |